// App-Quantinova.ai

TPS4617 : EA8185 Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration.

Researchers

Presenter

  • Monika Joshi

Principal Investigators

  • Se Eun Kim

  • Abhishek A Solanki

  • David Tomoaki Miyamoto

  • David Degraff

  • Jennifer Wei Zou

  • Joshua J Meeks

  • Timur Mitin

  • Sean P. Collins

  • Edouard John Trabulsi

  • Noah M. Hahn

  • Jason A. Efstathiou

  • Michael Anthony Carducci

Medical Centers

  • Penn State Cancer Institute, Hershey, PA

  • Dana-Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA

  • Loyola University Chicago, Maywood, IL

  • Massachusetts General Hosp Harvard Medcl School, Boston, MA

  • Pennsylvania State University College of Medicine, Hershey, PA

  • University of Pennsylvania, Philadelphia, PA

  • Jesse Brown VA Medical Center, Chicago, IL

  • Department of Radiation Medicine, Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Georgetown University, Washington, DC

  • Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA

  • Johns Hopkins Greenberg Bladder Center Institute, Johns Hopkins School of Medicine, Baltimore, MD

  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine,, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Durvalumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Prospective

Phase

  • II

Study Id's

  • NCT04216290

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved